If timelines shift but the product continues to improve and move closer to commercial reality, that’s credibility in action.
Kim’s credibility isn’t measured by whether he hit every timeline—it’s measured by whether he kept pushing, kept iterating, and kept making progress.
And he has.
Let’s face it this isn’t about facts anymore. It’s about your frustration over timelines and unmet expectations.
But frustration doesn’t equal fact.
Disappointment doesn’t equal deception.
And missed projections don’t equal incompetence.
You’re upset because you wanted a straight line to commercialization, and instead, you got a winding road filled with setbacks, adjustments, and breakthroughs.
But that’s how innovation works. That’s how biotech works.
The milestones are real.
The technology is working.
The path to commercialization is clear.
The only credibility issue here is your unwillingness to acknowledge progress because it doesn’t align with your personal expectations.
So keep chanting ‘credibility issue’ if it makes you feel better. But while you’re stuck on repeat, the rest of us will be watching KBLB move forward—toward commercialization, toward revenue, and toward success.
At the end of the day, Kim Thompson will be judged by results, not timelines. And if you can’t see that, the problem isn’t with him—it’s with you.
#KBLBProgress #FactsOverFrustration #InnovationIsntLinear
Bullish
Market Data 
Markets 
AI
